We are interested in programming biology at multiple levels of scale. Our contributions in this area include the early development of CRISPR-Cas9 for human genome editing, the discovery and development of CRISPR-Cas13d for transcriptome engineering, and the discovery and development of multiple classes of recombinases (bridge RNA-guided recombinases and new large serine recombinases) for large-scale DNA rearrangement and genome design. We are interested in applying these tools to manipulate higher-levels of biological organization at the tissue and physiological levels.
We aim to push the boundaries of synthetic biology, which we define broadly as anything that doesn‘t happen naturally. First, we think backwards from the desired application, such as a major unmet therapeutic need, and develop platform solutions that enable new kinds of synthetic manipulations. Recent areas of interest include cell type-specific control of biological perturbations, turning the dial on epigenetic memory, and manipulation of RNA splicing for writing RNAs directly into the endogenous transcriptome. We are also thinking about synthetic hormones, rational nutrition, and interoception.
Eric Nguyen, Michael Poli, Matthew G. Durrant, Armin W. Thomas, Brian Kang, Jeremy Sullivan, Madelena Y. Ng, Ashley Lewis, Aman Patel, Aaron Lou, Stefano Ermon, Stephen A. Baccus, Tina Hernandez-Boussard, Christopher Ré, Patrick D. Hsu, and Brian L. Hie
Matthew G. Durrant*, Nicholas T. Perry*, James J. Pai, Aditya R. Jangid, Januka S. Athukoralage, Masahiro Hiraizumi, John P. McSpedon, April Pawluk, Hiroshi Nishimasu, Silvana Konermann, Patrick D. Hsu
Matthew G. Durrant, Alison Fanton, Josh Tycko, Michaela Hinks, Sita S. Chandrasekaran, Nicholas T. Perry, Julia Schaepe, Peter P. Du, Peter Lotfy, Michael C. Bassik, Lacramioara Bintu, Ami S. Bhatt & Patrick D. Hsu
Sita S. Chandrasekaran, Shreeya Agrawal, Alison Fanton, Aditya R. Jangid, Bérénice Charrez, Arturo M. Escajeda, Sungmin Son, Roger Mcintosh, Huyen Tran, Abdul Bhuiya, María Díaz de León Derby, Neil A. Switz, Maxim Armstrong, Andrew R. Harris, Noam Prywes, Maria Lukarska, Scott B. Biering, Dylan C. J. Smock, Amanda Mok, Gavin J. Knott, Qi Dang, Erik Van Dis, Eli Dugan, Shin Kim, Tina Y. Liu, IGI Testing Consortium, Erica A. Moehle, Katherine Kogut, Brenda Eskenazi, Eva Harris, Sarah A. Stanley, Liana F. Lareau, Ming X. Tan, Daniel A. Fletcher, Jennifer A. Doudna, David F. Savage & Patrick D. Hsu
Scott B. Biering, Sylvia A. Sarnik, Eleanor Wang, James R. Zengel, Sarah R. Leist, Alexandra Schäfer, Varun Sathyan, Padraig Hawkins, Kenichi Okuda, Cyrus Tau, Aditya R. Jangid, Connor V. Duffy, Jin Wei, Rodney C. Gilmore, Mia Madel Alfajaro, Madison S. Strine, Xammy Nguyenla, Erik Van Dis, Carmelle Catamura, Livia H. Yamashiro, Julia A. Belk, Adam Begeman, Jessica C. Stark, D. Judy Shon, Douglas M. Fox, Shahrzad Ezzatpour, Emily Huang, Nico Olegario, Arjun Rustagi, Allison S. Volmer, Alessandra Livraghi-Butrico, Eddie Wehri, Richard R. Behringer, Dong-Joo Cheon, Julia Schaletzky, Hector C. Aguilar, Andreas S. Puschnik, Brian Button, Benjamin A. Pinsky, Catherine A. Blish, Ralph S. Baric, Wanda K. O’Neal, Carolyn R. Bertozzi, Craig B. Wilen, Richard C. Boucher, Jan E. Carette, Sarah A. Stanley, Eva Harris, Silvana Konermann & Patrick D. Hsu
Cheng Zhang, Silvana Konermann, Nicholas J. Brideau, Peter Lotfy, Xuebing Wu, Scott J. Novick, Timothy Strutzenberg, Patrick R. Griffin, Patrick D. Hsu, Dmitry Lyumkis
Preprint on bioRxiv
Silvana Konermann, Peter Lotfy, Nicholas J. Brideau, Jennifer Oki, Maxim N. Shokhirev, Patrick D. Hsu
Highlighted in Nature Methods, The CRISPR Journal, Alzforum
Patrick D. Hsu, Eric S. Lander, Feng Zhang
Nature Biotechnology
Nature Biomedical Engineering
Nature Genetics
Nature Chemical Biology
Patrick Hsu is Co-Founder of the Arc Institute and Assistant Professor of Bioengineering and Deb Faculty Fellow at the University of California, Berkeley. The Hsu lab works at the intersection of biology, engineering, and AI to develop technologies for biological programming and design. Patrick received A.M. and Ph.D. degrees from Harvard University and the Broad Institute, where he was an early pioneer of CRISPR-Cas9 technologies for genome editing. His research has been recognized by MIT Technology Review's Innovators Under 35, the Amgen Young Investigator Award, Forbes' 30 Under 30, the NIH Early Independence Award, and the Rainwater Prize for Innovative Early Career Scientist.
Massachusetts General Hospital/Harvard Medical School (Postdoc) & University of Wisconsin-Madison (PhD in Biochemistry)
Stanford (Postdoc) & Open University of London (PhD)
Stanford University (Postdoc) & University of Toronto (PhD in Pathobiology)
UC Berkeley (Postdoc) & Stanford University (PhD in Genetics)
UCSF (Postdoc) & University of St Andrews (PhD in Biochemistry)
PhD, Bioengineering, UC San Diego
Seoul National University (PhD in Biophysics)
UC Berkeley Chemistry PhD Program
Soros Fellow, UC Berkeley-UCSF Joint PhD Program in Bioengineering
NSF Fellow, UC Berkeley-UCSF Joint PhD Program in Bioengineering
UC Berkeley-UCSF Joint PhD Program in Bioengineering
UC Berkeley-UCSF Joint PhD Program in Bioengineering
UC Berkeley Molecular and Cell Biology PhD Program
B.S.E Chemical and Biomolecular Engineering, University of Pennsylvania
B.S. Bioengineering, B.S. EECS, UC Berkeley
UC Berkeley Bioengineering
.jpg&w=3840&q=75)
